Электронный архив

Granulocyte-macrophage colony-stimulating factor and car-t technology for solid tumors in experiment

Показать сокращенную информацию

dc.contributor.author Zaytsev D.V.
dc.contributor.author Zaikova E.K.
dc.contributor.author Golovkin A.S.
dc.contributor.author Bulatov E.R.
dc.contributor.author Valiullina A.K.
dc.contributor.author Mirgayazova R.M.
dc.contributor.author Daks A.A.
dc.contributor.author Zaritskey A.Y.
dc.contributor.author Petukhov A.V.
dc.date.accessioned 2021-02-25T20:52:39Z
dc.date.available 2021-02-25T20:52:39Z
dc.date.issued 2020
dc.identifier.issn 1997-6933
dc.identifier.uri https://dspace.kpfu.ru/xmlui/handle/net/162552
dc.description.abstract © 2020 Practical Medicine Publishing House. All rights reserved. Background. Cytokines are considered as important factors that enhance the efficacy of CAR-T cell therapy. Besides, they are key elements of the pathogenesis of cytokine release syndrome and neurotoxicity in applying the CAR-T technology. However, cytokine effects in the context of CAR-T therapy have not yet been properly studied. Aim. To quantitatively assess cytokine secretion using multiplex assay with co-incubation of anti-CD19 CAR-T lymphocytes with epithelial HeLa and A431 cell lines expressing CD19 on their surface. Materials & Methods. T-lymphocytes were transduced with the lentiviral vector containing anti-СD19-CAR gene. CAR expression was tested based on GFP reporter using flow cytometry. To confirm a specific CAR-T cell activation response to tumor antigen, the levels of interleukin-2, interferon-γ, and tumor necrosis factor-α were measured by means of immunoassay. Cytotoxic activity of CAR-T lymphocytes obtained was examined with their direct co-culturing with target cells. The levels of cytokines isolated prior to and after incubation of targets with CAR-T cells were compared using multiplex assay. Results. The level of some proinflammatory cytokines (interleukin-6, interleukin-1β, interferon-γ) (p < 0.01) increased. The difference in the levels of anti-inflammatory cytokines (interleukin-4, interleukin-10) was inconsiderable, and in the HeLa cell line experiment it was insignificant (p > 0.05). The concentration of granulocyte-macrophage colony-stimulating factor (GM-CSF) was many times higher after incubation with CAR-T lymphocytes (p < 0.01). Conclusion. The trial revealed multiple enhancement of GM-CSF, one of the key elements of the pathogenesis of cytokine release syndrome and CAR-T-associated neurotoxicity. The results of further studies of GM-CSF can contribute to improving the efficacy of CAR-T therapy with considerably lower toxicity.
dc.relation.ispartofseries Klinicheskaya Onkogematologiya/Clinical Oncohematology
dc.subject CAR-T cells
dc.subject Cytokines
dc.subject GM-CSF
dc.subject Immunotherapy
dc.title Granulocyte-macrophage colony-stimulating factor and car-t technology for solid tumors in experiment
dc.type Article
dc.relation.ispartofseries-issue 2
dc.relation.ispartofseries-volume 13
dc.collection Публикации сотрудников КФУ
dc.relation.startpage 115
dc.source.id SCOPUS19976933-2020-13-2-SID85097267491


Файлы в этом документе

Данный элемент включен в следующие коллекции

  • Публикации сотрудников КФУ Scopus [24551]
    Коллекция содержит публикации сотрудников Казанского федерального (до 2010 года Казанского государственного) университета, проиндексированные в БД Scopus, начиная с 1970г.

Показать сокращенную информацию

Поиск в электронном архиве


Расширенный поиск

Просмотр

Моя учетная запись

Статистика